<DOC>
	<DOCNO>NCT01528046</DOCNO>
	<brief_summary>H. Lee Moffitt Cancer Center Research Institute Sunshine Project Coordinator , recruit locally . The purpose study evaluate tolerability safety escalate dos metformin backbone vincristine , irinotecan temozolomide ( VIT ) child recurrent refractory solid tumor .</brief_summary>
	<brief_title>Metformin Children With Relapsed Refractory Solid Tumors</brief_title>
	<detailed_description>Metformin oral anti-diabetes medication activate AMP-activated protein kinase ( AMPK ) . Recent data vitro vivo experiment , well epidemiologic retrospective analysis , suggest metformin anti-cancer activity . Vincristine , irinotecan , temozolomide ( VIT ) combination chemotherapeutic agent different mechanism action well disparate side effect profile . Two recent phase 1 trial demonstrate regimen safe well-tolerated child relapse refractory solid tumor .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Age : Patients must &gt; 1 year age ≤ 18 year age time initiation protocol therapy . Diagnosis : Patients histologically radiographically confirm relapsed refractory solid tumor primary central nervous system ( CNS ) malignancy . Disease Status : Patients must radiographically measurable disease . Therapeutic Options : Patients must relapse refractory cancer know curative option available therapy proven prolong survival acceptable quality life . Performance Level : Karnofsky ≥ 50 % patient old 16 year old , Lansky ≥ 50 patient 116 year old . Prior Therapy : Patients may receive prior therapy include vincristine , irinotecan , temozolomide . Patients may previously treat combination therapy irinotecan temozolomide . Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . Myelosuppressive chemotherapy : Patients must receive myelosuppressive chemotherapy within 3 week start protocol therapy , minimum six week must elapse since prior nitrosurea chemotherapy . Hematopoietic growth factor : At least 7 day must elapse since last administration filgrastim , 14 day since administration pegfilgrastim . Biologic ( antineoplastic agent ) : At least 7 must elapse since last administration biologic agent . Radiation therapy ( XRT ) : At least 14 day since last dose local palliative radiation therapy . Greater 6 month must elapse since last day treatment give total body irradiation , craniospinal irradiation . Autologous Allogenic Stem Cell Transplant : Complete resolution graft versus host disease current need immunosuppressive medication . Greater 3 month must elapse since engraftment longer require transfusion platelet injection colony stimulating factor . Organ Function Requirements Bone Marrow Function : Peripheral absolute neutrophil count ( ANC ) ≥ 1000/μL ; Platelet count ≥ 100,000/μL ( platelet transfusion within 7 day prior obtain laboratory result ) ; Hemoglobin ≥ 8.0 gm/dL Adequate Renal Function : Creatinine clearance glomerular filtration rate ≥ 70ml/min/1.73m^2 Adequate Liver Function : Total bilirubin ≤ 1.5x upper limit normal ( ULN ) age ; alanine transaminase ( ALT ) ≤ 5x ULN ; Serum albumin ≥ 2gm/dL Informed Consent : All patient ≥ 18 year age must sign write informed consent . For patient &lt; 18 year old , patient 's parent legal guardian must sign write informed consent , unless patient emancipate minor . Childhood Assent , age appropriate per institutional guideline , sign participate patient . Significant organ dysfunction , meet inclusion criterion . Pregnancy BreastFeeding woman enter study due risk fetal teratogenic adverse event see animal/human study . Concomitant Medications : Growth factor : Growth factor support platelet white cell number function must administer within past 7 day . Steroids : Patients CNS tumor stable decrease dose dexamethasone past 7 day . Investigational Drugs : Patients currently receive another investigational drug . Anticancer Agents : Patients currently receive anticancer agent . Medication Allergy : Allergy intolerance agent protocol : vincristine , irinotecan , temozolomide , metformin ; Allergy cephalosporin . Infection : Patients uncontrolled infection , positive blood culture within past 48 hour , receive treatment Clostridium difficile infection .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>central nervous system ( CNS )</keyword>
	<keyword>malignancy</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>pediatric</keyword>
	<keyword>recurrent</keyword>
</DOC>